SHORT-TERM OUTCOMES AFTER INTERIM TREATMENT WITH BROLUCIZUMAB: A Retrospective Case Series of a Single Center Experience

Conclusion: Interim treatment with brolucizumab resulted in anatomical improvements in 41 eyes (41/51%, 80%) that were maintained in 22 of these eyes (22/41%, 54%) for at least 6 months after switching back to the original anti–vascular endothelial growth factor therapeutic. There were no corresponding significant changes in visual acuity.
Source: RETINA - Category: Opthalmology Tags: Original Study Source Type: research